These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15681541)

  • 1. Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
    Noberasco C; De Pas T; Curigliano G; Manzoni S; Dodaro L; Pelosi G; Spaggiari L; De Braud F
    J Clin Oncol; 2005 Feb; 23(4):921-2; author reply 922. PubMed ID: 15681541
    [No Abstract]   [Full Text] [Related]  

  • 2. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
    Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
    J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Bunn PA; Franklin WA; Dziadziuszko R; Thatcher N; Chang A; Parikh P; Pereira JR; Ciuleanu T; von Pawel J; Watkins C; Flannery A; Ellison G; Donald E; Knight L; Parums D; Botwood N; Holloway B
    J Clin Oncol; 2006 Nov; 24(31):5034-42. PubMed ID: 17075123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
    Cappuzzo F; Ligorio C; Jänne PA; Toschi L; Rossi E; Trisolini R; Paioli D; Holmes AJ; Magrini E; Finocchiaro G; Bartolini S; Cancellieri A; Ciardiello F; Patelli M; Crino L; Varella-Garcia M
    J Clin Oncol; 2007 Jun; 25(16):2248-55. PubMed ID: 17538169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib versus cetuximab in lung cancer: round one.
    Minna JD; Peyton MJ; Gazdar AF
    J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
    [No Abstract]   [Full Text] [Related]  

  • 7. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
    Fidler MJ; Basu S; Buckingham L; Walters K; McCormack S; Batus M; Coon J; Bonomi P
    Anticancer Res; 2012 May; 32(5):1705-10. PubMed ID: 22593449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
    Friess T; Scheuer W; Hasmann M
    Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
    Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
    Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.
    Soh J; Toyooka S; Ichihara S; Fujiwara Y; Hotta K; Suehisa H; Kobayashi N; Ichimura K; Aoe K; Aoe M; Kiura K; Date H
    Int J Cancer; 2007 Sep; 121(5):1162-7. PubMed ID: 17487844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib. Still no convincing results in non-small cell lung cancer.
    Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
    Normanno N; Di Maio M; Perrone F; Campiglio M
    J Clin Oncol; 2004 May; 22(10):2035-6; author reply 2036-7. PubMed ID: 15143103
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictors of clinical response of non-small cell cancer to gefitinib.
    Ardizzoni A; Tiseo M
    JAMA; 2004 Apr; 291(13):1563; author reply 1563-4. PubMed ID: 15069041
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-small-cell lung cancer third-line therapy with gefitinib].
    Fischer JR; Haffner U; Dietrich GM; Spahlinger B; Geiger D; Lahm H
    Pneumologie; 2005 May; 59(5):321-7. PubMed ID: 15902597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
    Viswanathan A; Pillot G; Govindan R
    Lung Cancer; 2005 Dec; 50(3):417-8. PubMed ID: 16129510
    [No Abstract]   [Full Text] [Related]  

  • 17. Gefitinib for refractory advanced non-small-cell lung cancer.
    Moriguchi H; Kim TY; Sato C
    Lancet; 2006 Jan; 367(9507):299-300. PubMed ID: 16443032
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
    Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
    Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.